ZEB1 and neoplasm: Here, knock-down of ZEB1 in B16-F10 CD133+/CD44+ CSCs results in significantly reduced clonogenicity, proliferation and migratory properties in vitro and reduced tumour growth and lung tumour metastasis in vivo.